INmune Bio Inc Market Cap ($36.64 Million)
Market Cap & Net Worth: INmune Bio Inc (INMB)
INmune Bio Inc market cap. INmune Bio Inc (NASDAQ:INMB) has a market capitalization of $36.64 Million ($36.64 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22841 globally and #5026 in its home market, demonstrating a -7.69% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying INmune Bio Inc's stock price $1.32 by its total outstanding shares 27753789 (27.75 Million). Also see INmune Bio Inc (INMB) cash conversion ratio for how efficiently the company converts equity into cash flow.
INmune Bio Inc Market Cap History (2019–2026)
INmune Bio Inc market cap history from 2019 to 2026. Data shows change from $160.97 Million to $36.64 Million (-20.73% CAGR). Check INMB share price today for real-time trading data and today's change.
Index Memberships
INmune Bio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #643 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2142 of 3165 |
Weight: INmune Bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
INmune Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how INmune Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore INMB shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
865.92x
INmune Bio Inc's market cap is 865.92 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $160.97 Million | $77.69 Million | -$7.68 Million | 2.07x | N/A |
| 2020 | $477.92 Million | $10.92K | -$12.10 Million | 43781.63x | N/A |
| 2021 | $283.09 Million | $181.00K | -$30.34 Million | 1564.03x | N/A |
| 2022 | $175.96 Million | $374.00K | -$28.65 Million | 470.48x | N/A |
| 2023 | $312.51 Million | $155.00K | -$30.01 Million | 2016.18x | N/A |
| 2024 | $129.61 Million | $14.00K | -$42.08 Million | 9257.87x | N/A |
| 2025 | $43.30 Million | $50.00K | -$45.93 Million | 865.92x | N/A |
Competitor Companies of INMB by Market Capitalization
Companies near INmune Bio Inc in the global market cap rankings as of November 5, 2026. Also see INmune Bio Inc asset portfolio for a full breakdown of the balance sheet.
Key companies related to INmune Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of INmune Bio Inc (2019–2026)
Market capitalization of INmune Bio Inc from 2019 to today. Between 2019 and today, INmune Bio Inc's market cap moved from $160.97 Million to $ 36.64 Million, with a yearly change of -20.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $36.64 Million | -15.38% |
| 2025 | $43.30 Million | -66.60% |
| 2024 | $129.61 Million | -58.53% |
| 2023 | $312.51 Million | +77.60% |
| 2022 | $175.96 Million | -37.84% |
| 2021 | $283.09 Million | -40.77% |
| 2020 | $477.92 Million | +196.90% |
| 2019 | $160.97 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of INmune Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.64 Million USD |
| MoneyControl | $36.64 Million USD |
| MarketWatch | $36.64 Million USD |
| marketcap.company | $36.64 Million USD |
| Reuters | $36.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About INmune Bio Inc
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of pati… Read more